Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials

Jain, Rakesh K.; Chen, Dalei; Edwards, J.B.; Mathews, Maju

doi:10.1185/03007995.2013.855188

Cited by 17 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant differences from placebo occurred at week 1 and week 6 in the two Phase III trials. In the pooled data, a statistically significant difference from placebo occurred with vilazodone at week 1 on MADRS total score and on 7 of 10 MADRS single items at week 1 or 2 [75]. It should be noted that the Phase III studies used a titration design, meaning that subtherapeutic doses of 10 mg were used at week 1.…”

Section: Onset Of Actionmentioning

confidence: 94%

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

Deardorff

Grossberg

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

All three drugs are effective in the treatment of MDD, but data comparing them to other antidepressants is currently lacking. Vilazodone was proposed to produce a more rapid onset and have fewer sexual side effects but neither effect has been conclusively shown. Levomilnacipran appears to be effective in improving functional impairment, including both social and work functioning. Vortioxetine is currently the only drug of the three with proven efficacy in elderly patients. It also appears to have cognitive enhancing properties which are largely independent of improved depressive symptoms. Overall, these drugs represent a promising step forward in antidepressant drug development.

show abstract

Section: Onset Of Actionmentioning

confidence: 94%

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

Deardorff

Grossberg

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…In this category, vilazodone, a 5-HT1A receptor partial agonist and SSRI [86][87][88], offers a new therapeutic possibility [89,90]. It has been shown that vilazodone induces an elevation of 5-HT amounts in the medial and the lateral cortex that is six-fold higher than those induced by SSRIs paroxetine, citalopram or fluoxetine [86].…”

Section: Effects Of Novel Strategiesmentioning

confidence: 99%

Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies

Haddjeri¹

2014

AAD

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is a common illness worldwide with severe socioeconomic consequences. Several hypotheses have been formulated to explain the physiopathology of depression as well as the mechanism of action of antidepressants but two of them had attracted much attention. The dominant monoaminergic hypothesis of depression links the physiopathology of MDD to a deficiency on cerebral serotonin (5-HT) and/or Norepinephrine (NE) levels; however, the relatively new neurogenic and neurotrophic hypothesis raises the possibility of an impaired neuroplasticity and/or depletion of neurotrophic factors in specific networks resulting on their structural deformity and functional impairment. An enormous body of evidence reported particular neuroadaptations following chronic administration of antidepressant drugs. In this review, we describe major adaptive changes in pre-and post-synaptic 5-HT neurotransmission as well as alterations in gene transcription and neurotrophic factors in response to long-term treatment with conventional antidepressants, new putative ones or novel promising drug candidates, all acting via 5-HT system.

show abstract

“… 12 Because of its unique action mechanism, indirect evidence enabled clinicians to speculate that vilazodone may potentially provide faster treatment onset along with enhanced remission and response rates with lower AE risks than preexisting anti-depressants. 13 , 14 , 15 Preclinical studies and indirect evidences did suggest that vilazodone might result in faster treatment onset than conventional selective serotonin reuptake inhibitors (SSRIs), 16 , 17 but no direct comparative trials confirmed vilazodone's superiority over other antidepressants.…”

Section: Introductionmentioning

confidence: 99%

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action

Wang

Han

Lee

et al. 2015

Psychiatry Investig

View full text Add to dashboard Cite

We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions, we sought to elaborate them mainly through preclinical animal studies. A data search was conducted in November 1, 2013, using the key terms "vilazodone" or "Viibryd," in PubMed and Medline databases. All published and unpublished studies are included and citations from publications were also reviewed for additional references. Five unpublished, phase-II and two pivotal published phase-III clinical trials with nearly identical design (8-week, double-blind, randomized, and placebo-controlled) investigated efficacy of vilazodone, were found for the treatment of patients with MDD. Two post-hoc studies and one long-term open study were also included. Data were thoroughly reviewed to incorporate the pharmacology, action mechanism, efficacy and safety for the vilazodone in the treatment of major depressive disorder. Vilazodone is an antidepressant with novel mechanism of action because its chemical structure is unrelated to conventional antidepressant, and it has a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile. Vilazodone is an effective and safe treatment option with its novel action mechanisms for patients with depression. Its putative benefits compared with other antidepressants must be thoroughly studied in adequately-powered and well-designed future clinical trials.

show abstract

Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials

Abstract: Early and sustained improvement of depressive symptoms was retrospectively observed in patients treated with vilazodone; early findings may be related to overall treatment outcomes.

Cited by 17 publications

References 26 publications

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action

Contact Info

Product

Resources

About